Capital Impact Advisors LLC raised its holdings in Editas Medicine Inc (NASDAQ:EDIT) by 21.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 57,406 shares of the company’s stock after buying an additional 10,138 shares during the period. Capital Impact Advisors LLC’s holdings in Editas Medicine were worth $1,861,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. TRUE Private Wealth Advisors bought a new position in shares of Editas Medicine in the third quarter valued at $137,000. Asset Dedication LLC lifted its position in shares of Editas Medicine by 4,400.0% during the second quarter. Asset Dedication LLC now owns 4,500 shares of the company’s stock valued at $161,000 after purchasing an additional 4,400 shares in the last quarter. Reynders McVeigh Capital Management LLC bought a new position in shares of Editas Medicine during the second quarter valued at about $202,000. Telos Capital Management Inc. bought a new position in shares of Editas Medicine during the second quarter valued at about $203,000. Finally, Element Capital Management LLC bought a new position in shares of Editas Medicine during the first quarter valued at about $201,000. 67.18% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Katrine Bosley sold 12,000 shares of the firm’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $30.17, for a total transaction of $362,040.00. Following the completion of the sale, the chief executive officer now owns 1,270,399 shares in the company, valued at $38,327,937.83. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CTO Vickesh Myer sold 4,000 shares of the firm’s stock in a transaction dated Thursday, October 18th. The stock was sold at an average price of $29.44, for a total transaction of $117,760.00. Following the sale, the chief technology officer now owns 3,000 shares of the company’s stock, valued at approximately $88,320. The disclosure for this sale can be found here. Insiders have sold 76,333 shares of company stock valued at $2,370,840 in the last 90 days. 5.20% of the stock is currently owned by corporate insiders.

EDIT opened at $27.49 on Friday. Editas Medicine Inc has a fifty-two week low of $20.29 and a fifty-two week high of $45.02. The company has a debt-to-equity ratio of 0.14, a quick ratio of 14.50 and a current ratio of 14.50. The stock has a market cap of $1.41 billion, a P/E ratio of -9.23 and a beta of 3.37.

Editas Medicine (NASDAQ:EDIT) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.15). Editas Medicine had a negative return on equity of 61.27% and a negative net margin of 623.35%. The company had revenue of $7.37 million for the quarter, compared to analysts’ expectations of $7.01 million. During the same quarter last year, the business posted ($0.65) EPS. The business’s quarterly revenue was up 137.7% on a year-over-year basis. Equities research analysts predict that Editas Medicine Inc will post -3 EPS for the current fiscal year.

A number of research analysts recently weighed in on the stock. Guggenheim assumed coverage on shares of Editas Medicine in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock. BidaskClub raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Tuesday, August 21st. Raymond James assumed coverage on shares of Editas Medicine in a research report on Friday, September 21st. They set an “outperform” rating and a $40.00 price target on the stock. JPMorgan Chase & Co. set a $36.00 price target on shares of Editas Medicine and gave the company a “hold” rating in a research report on Monday, August 6th. Finally, Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $46.50.

Editas Medicine Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Read More: S&P 500 Index

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.